ROCSAN

Trial Description: 
A Multicentric Randomized Phase II/III Evaluating TSR-042 (Anti-PD-1 mAb) in Combination With Niraparib (Parpi) Versus Niraparib Alone Compared to Chemotherapy in the Treatment of Metastatic or Recurrent Endometrial or Ovarian Carcinosarcoma After at Least One Line of Chemotherapy
Lead Cooperative Group: 
Participating Groups: 
Disease Site: 
Ovarian/Rare
Trial Status: 
Recruiting
Contact person: